These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234 [TBL] [Abstract][Full Text] [Related]
13. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors. Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972 [TBL] [Abstract][Full Text] [Related]
14. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Lopez WO; Cordeiro JG; Albicker U; Doostkam S; Nikkhah G; Kirch RD; Trippel M; Reithmeier T Onco Targets Ther; 2015; 8():3803-15. PubMed ID: 26719708 [TBL] [Abstract][Full Text] [Related]
15. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081 [TBL] [Abstract][Full Text] [Related]
16. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607 [TBL] [Abstract][Full Text] [Related]
17. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172 [TBL] [Abstract][Full Text] [Related]
18. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606 [TBL] [Abstract][Full Text] [Related]
19. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047 [TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]